Next 10 |
2024-03-26 21:49:10 ET Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Conference Call March 26, 2024 04:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer C...
2024-03-26 16:14:50 ET More on Panbela Therapeutics Panbela Therapeutics closes ~$9M public offering of shares Panbela Therapeutics drops on $9M public offering Seeking Alpha’s Quant Rating on Panbela Therapeutics Historical earnings data for Panbela T...
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on...
2024-02-15 09:22:43 ET More on Panbela Therapeutics Panbela Therapeutics closes ~$9M public offering of shares Panbela Therapeutics drops on $9M public offering Seeking Alpha’s Quant Rating on Panbela Therapeutics Read the full article on Seeking Alp...
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with appl...
Panbela (NASDAQ: PBLA) is a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company today announced the closing of its public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof a...
2024-02-01 07:46:07 ET More on Panbela Therapeutics Panbela Therapeutics, Inc. (PBLA) Q3 2023 Earnings Call Transcript Panbela Therapeutics drops on $9M public offering Panbela conducting 1-for-20 reverse stock split Thursday Seeking Alpha’s Quant Rati...
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering ...
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on...